Sonia Poli, Laura RodrĂguez-Pascau, Elena Britti, Joaquim Ros, Pilar González-Cab, David Lynch, Marc Martinell, Pilar Pizcueta; Neurology Apr 2020, 94 (15 Supplement) 4147;
The preclinical results support the investigation of leriglitazone for the treatment of FRDA. Leriglitazone is currently in clinical phase 2/3 for the treatment of AMN, in phase 2 for cALD and in phase 2 for Friedreich’s Ataxia.
Subscribe to:
Posts (Atom)
